Share on StockTwits

Concert Pharmaceuticals (NASDAQ:CNCE) issued its quarterly earnings data on Tuesday. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.42) by $0.03, AnalystRatings.Net reports.

Concert Pharmaceuticals (NASDAQ:CNCE) opened at 8.17 on Tuesday. Concert Pharmaceuticals has a 52 week low of $7.12 and a 52 week high of $16.26. The stock’s 50-day moving average is $8.75 and its 200-day moving average is $10.56. The company’s market cap is $146.2 million.

CNCE has been the subject of a number of recent research reports. Analysts at Roth Capital reiterated a “buy” rating on shares of Concert Pharmaceuticals in a research note on Tuesday, July 8th. On a related note, analysts at Ladenburg Thalmann initiated coverage on shares of Concert Pharmaceuticals in a research note on Thursday, June 26th. They set a “buy” rating and a $24.00 price target on the stock.

Concert Pharmaceuticals Inc is a United States-based company that is engaged in the pharmaceutical preparation and research industry.

Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.